Cinclus Pharma Q2 FY26 operating loss widens to SEK 95.03 million; net loss deepens to SEK 78.76 million

• Cinclus Pharma posted an operating loss of SEK 95.03 million for April–June 2026, widening from SEK 45.91 million a year earlier.
• Net sales fell to SEK 1.77 million from SEK 34.1 million in the year-ago quarter.
• Net loss widened to SEK 78.76 million; loss per share deepened to SEK 1.69.
• Total cash flow was SEK -91.35 million; cash and cash equivalents ended the quarter at SEK 387.92 million.
• Phase III HEEALING1 completed enrollment with 521 patients randomized; topline results are expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cinclus Pharma Holding AB (Publ) published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.